Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: olema.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2025 | $20.00 → $21.00 | Buy | Citigroup |
| 4/2/2024 | $24.00 | Buy | Goldman |
| 1/30/2024 | $20.00 | Buy | Citigroup |
| 7/21/2023 | $21.00 | Outperform | Oppenheimer |
| 5/5/2023 | $16.00 | Overweight | CapitalOne |
| 2/22/2023 | $12.00 | Outperform | Credit Suisse |
| 7/6/2022 | $16.00 | Buy | Canaccord Genuity |
| 6/9/2022 | $12.00 | Neutral → Buy | H.C. Wainwright |
| 2/28/2022 | Neutral | HC Wainwright & Co. | |
| 12/7/2021 | Outperform | Cowen |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
DEFA14A - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
DEF 14A - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
S-8 - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
10-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup reiterated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously
Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Oppenheimer initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $21.00
CapitalOne initiated coverage of Olema Pharmaceuticals with a rating of Overweight and set a new price target of $16.00
Credit Suisse initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $12.00
Canaccord Genuity resumed coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $16.00
H.C. Wainwright upgraded Olema Pharmaceuticals from Neutral to Buy and set a new price target of $12.00
HC Wainwright & Co. initiated coverage of Olema Pharmaceuticals with a rating of Neutral
Cowen resumed coverage of Olema Pharmaceuticals with a rating of Outperform
Fastest customizable press release news feed in the world
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dyn
Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025Mature data from the Phase 1b/2 study of palazestrant in combination with ribociclib to be presented at ESMO 2025 Ended the second quarter with $361.9 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development,
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 130,000 shares of the Company's common stock, effective as of August 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance
SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares of the Company's common stock, effective as of July 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w
SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 11 new employees to purchase an aggregate of 322,000 shares of the Company's common stock, effective as of June 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance wit
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm CT / 10:00am–1:00pm ET SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoi
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Jefferies Global Healthcare ConferenceDate and Time: Wednesday, June 4, 2025 at 11:40 a.m. ETFormat: Fireside ChatLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate and Time: Wednesday, June 11, 2025 at 8 a.m. ETFormat: Fireside ChatLocation: Miami, FL Live webcasts and recordings o
Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 studyPivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual MeetingPreclinical data for OP-3136 presented at AACR demonstrating anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models; Phase 1 trial recruitment ongoingEnded the first quarter with $392.7 million in cash, cash equivalents, and marketabl
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference Date: Tuesday, May 20, 2025 at 4:30 p.m. ETFormat: Fireside Chat Location: New York, NY T.D. Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO and EHADate: Tuesday, May 27, 2025 at 5 p.m. ETFormat: Fireside ChatLocation: Virtual Live webcasts and recor
SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares of the Company's common stock, effective as of May 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance wit
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Live Leadership Updates
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarterNew clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in December Strong cash, cash equivalents and marketable securities position of $276.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancer
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the appointment of Scott Garland to the company's Board of Directors. Mr. Garland brings more than 30 years of biopharmaceutical industry experience with deep commercial and executive leadership expertise. "We are delighted to have Scott join our Board of Directors at such an exciting time for Olema," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "His broad experien
• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema's Scientific Advisory Board SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced the appointment of Naseem Zojwalla, M.D., as Chief Medical Officer. Bringing more than 15 years of oncology and clinical deve
Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its PipelineLongstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema’s Scientific Advisory Board SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the appointment of Yi Larson to the company’s Board of Directors, and the transition of lon
Live finance-specific insights
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Poster Details Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patien
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to be presented at the ESMO Breast Cancer Annual Congress 2024 in Berlin, Germany. Olema will host an investor conference call on May 15, 2024, at 8:00 a.m. ET to review the dataInvestigational New Drug (IND) application for OP-3136, a novel KAT6 inhibitor, expected to be filed with FDA in late 2024Cash, cash equivalents and marketable securities of $249.0 million as of March 31, 2024 SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will present new clinical data from the Company's ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 2024 taking place May 15-17, 2023, in Berlin, Germany. Details of the ESMO Breast Cancer Annual Congress 2024 poster presentation are: Title:
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved labels of ribociclib or palbociclib plus an endocrine therapyOPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023Olema will host an investor conference call at 8:00 a.m. ET on December 6, 2023 SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on t
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023 Olema will host an investor conference call at 8:00 a.m. ET on Dec. 8, 2023 SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will be presenting new Phase 1b/2 cli
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis of 49 second- and third-line patients, the median PFS was 7.2 months with a CBR of 48%; the median PFS was 7.3 months with a CBR of 59% in patients with ESR1 mutations Results support continued development of palazestrant in the OPERA-01 monotherapy Phase 3 pivotal trialOlema will host an investor conference call at 8:00 a.m. ET on Monday, October 23, 2023 SAN FRANCISCO, Oct. 22, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", or the "Company", NASDAQ:OLMA),
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23, 2023 SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced an oral presentation on the Phase 2 monotherapy study results of palazestrant (OP-1250), the Company's complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) for the treatme
OP-1250 continues to demonstrate favorable tolerability, high drug exposure, and strong anti-tumor activity in preliminary Phase 1/2 study results presented at the 34th EORTC-NCI-AACR SymposiumInitial clinical data for OP-1250 in combination with CDK 4/6 inhibitor palbociclib expected in the fourth quarter of 2022Pivotal monotherapy Phase 3 study planned for initiation mid-2023Company to host investor conference call today at 8:00 a.m. ET SAN FRANCISCO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology" or the "Company", NASDAQ:OLMA) today announced preliminary clinical results from a Phase 1/2 clinical study of OP-1250, the Company's complete est
This live feed shows all institutional transactions in real time.
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)